Edition:
India

OncoSec Medical Inc (ONCS.OQ)

ONCS.OQ on NASDAQ Stock Exchange Capital Market

2.04USD
19 Jan 2018
Change (% chg)

$-0.07 (-3.32%)
Prev Close
$2.11
Open
$2.10
Day's High
$2.11
Day's Low
$1.90
Volume
163,145
Avg. Vol
347,645
52-wk High
$2.95
52-wk Low
$0.88

Latest Key Developments (Source: Significant Developments)

Oncosec Plans To Conduct A Second Clinical Trial In Triple Negative Breast Cancer In 2018​
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Oncosec Medical Inc ::ONCOSEC PROVIDES 2018 BUSINESS OUTLOOK.ONCOSEC MEDICAL INC - PLAN TO CONDUCT A SECOND CLINICAL TRIAL IN TRIPLE NEGATIVE BREAST CANCER IN 2018​.ONCOSEC MEDICAL -‍PLAN TO CONDUCT 2 INVESTIGATOR SPONSORED TRIALS IN SQUAMOUS CELL CARCINOMA OF HEAD, NECK AND IN MELANOMA NEOADJUVANT SETTING IN 2018​.ONCOSEC MEDICAL INC - PREPARE TO COMMERCIALLY LAUNCH IMMUOPULSE IL-12 IN U.S. IN 2018.  Full Article

Oncosec Announces Dosing Of First Patient In Registration-Directed Phase 2B Clinical Trial
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Oncosec Medical Inc ::ONCOSEC ANNOUNCES DOSING OF FIRST PATIENT IN REGISTRATION-DIRECTED PHASE 2B CLINICAL TRIAL, PISCES/KEYNOTE-695, OF IMMUNOPULSE® IL-12 IN COMBINATION WITH PEMBROLIZUMAB.  Full Article

OncoSec Medical files for offering of up to 6.83 mln shares
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Oncosec Medical Inc -:OncoSec Medical Inc files for offering of up to 6.83 million shares of co's common stock by the selling shareholders - SEC filing.  Full Article

Oncosec announces positive follow-up data from phase 2 trial of Immunopulse il-12
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Oncosec Medical Inc :Oncosec announces positive updated long-term follow-up data from phase 2 trial of Immunopulse il-12 in combination with pembrolizumab demonstrating a progression free survival rate (PFS) of 57% at 15 months in predicted anti-pd-1 non-responder melanoma p.  Full Article

Oncosec appoints Daniel O'Connor as CEO
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Oncosec Medical Inc :Oncosec appoints Daniel J. O'Connor as chief executive officer to lead next stage of growth as a fully integrated late stage development and commercial company.Oncosec medical - ‍punit Dhillon, co-founder of Oncosec, will continue to serve as company's president and a member of its board​.  Full Article

Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical
Wednesday, 1 Nov 2017 

Oct 31 (Reuters) - OncoSec Medical Inc :Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical Inc, as of October 22, 2017‍​.  Full Article

OncoSec Q4 loss per share $0.28
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - OncoSec Medical Inc : :OncoSec announces fourth quarter and year end financial results for fiscal year 2017.Q4 loss per share $0.28.OncoSec medical - ‍expects current funds to be sufficient to allow co to continue to operate business to third calendar quarter of 2018​.  Full Article

Oncosec Medical Inc says has ‍initiated phase 2b registration directed trial, pisces/keynote-695
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Oncosec Medical Inc :Oncosec initiates registration directed clinical trial, keynote-695, of immunopulse® il-12 in combination with merck's keytruda® (pembrolizumab).Oncosec Medical Inc - ‍initiated phase 2b registration directed trial, pisces/keynote-695.  Full Article

Oncosec Q4 loss per share $0.39
Friday, 14 Oct 2016 

Oncosec Medical Inc : Oncosec announces fourth quarter and year end results for fiscal year 2016 . Q4 loss per share $0.39 .Oncosec Medical Inc - Qtrly net loss $6.6 million versus $6.5 million.  Full Article

Oncosec posts Q3 loss per share $0.37
Friday, 10 Jun 2016 

Oncosec Medical Inc : Oncosec announces third quarter and YTD results for fiscal year 2016 . Q3 loss per share $0.37 .Expects funds to be sufficient to allow it to continue to operate its business for at least next 12 months.  Full Article

BRIEF-OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study

* ONCOSEC PROVIDES ENCOURAGING CLINICAL OBSERVATIONS RELATED TO TRIPLE NEGATIVE BREAST CANCER STUDY Source text for Eikon: Further company coverage: